Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Alaunos Therapeutics, Inc. (TCRT)

NCM · Biotechnology

$1.90-0.00 (-0.01%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$4.6M
P/E (TTM)
EPS
$-2.09
Div Yield
52W Range
$1.67–$4.59
Beta
-1.02

Company overview

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Peers in Biotechnology

All in industry →

Recent press releases

Alaunos Therapeutics, Inc. has not issued a press release in this window.

SEC filings

All filings →

Alaunos Therapeutics, Inc. has not filed an SEC document in this window.

Alaunos Therapeutics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-03-31 · prior 2024-12-31
14,940 sh● NEW

People at Alaunos Therapeutics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$1.1M
06/25
NI -$1.1M
09/25
NI -$1.2M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.55
Prior: $-0.63
Revenue sparkline